The agreement will allow Mayo Clinic to become a shareholder in AccuLine.
The CORA system is designed to simultaneously measure and interpret several biological indicators, covering respiratory rhythm, cardiac electrical activity and blood oxygen saturation.
Leveraging artificial intelligence (AI)-driven signal processing algorithms, the system enables the assessment of the individual’s coronary arteries.
The technology is based on the two novel bio-signal discoveries in the electric activity of the heart, correlating with CAD.
With a specificity and sensitivity of 85%, the system was able to differentiate between individuals with and without notable coronary heart disease in a clinical trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The collaboration aims to adapt the system for the US market, which involves defining features of the product and designing a comprehensive clinical trial in line with FDA approval requirements.
Furthermore, the technology will be integrated as the preferred diagnostic tool for cardiologists and general practitioners for early detection of CAD.
AccuLine CEO Moshe Barel said: “We are thrilled to join forces with Mayo Clinic in this pivotal initiative aimed at reducing the impact of heart attacks on mortality and patient well-being.
“Mayo Clinic’s extensive clinical experience and expertise in diagnosing and treating cardiac conditions are important assets as we refine CORA, enabling the identification of individuals at high risk for heart attacks years in advance.”